Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-nCoV Efficacy, Safety and Immunogenicity in Adults
NCT04526990Phase 3Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 3 trial of ad5-ncov in coronavirus disease 2019 (COVID-19), sponsored by CanSino Biologics Inc.. Started Sep 2020; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04526990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526990.